Inflammation News and Research

RSS

Researchers identify new therapeutic target for Duchenne muscular dystrophy

Scientists have found what could one day lead to a promising treatment for those with a crippling disease, Duchenne muscular dystrophy.

14 Oct 2015

Researchers find protein that plays crucial role in development of allergic airway inflammation

Allergies are becoming more commonplace, particularly in industrialised coun-tries. In addition to hay fever, allergic asthma is currently considered to be one of the most widespread allergies. UFZ researchers and their colleagues from the University of Leipzig have recently been successful in finding a protein that plays a critical role in the development of allergic airway inflammation.

12 Oct 2015

Glycan binding proteins modify parasite infection in cells of the heart muscle

Chagas disease is the main cause of infectious heart disease in Latin America. Researchers from the INGEBI and IBYME Institutes in Argentina explored the effect of glycan binding protein interactions between the human host and Typanosoma cruzi parasite. They found that a glycan binding protein expressed in humans modified the infection in cells of the heart muscle, showing the importance of galectins in the response to parasite infection.

12 Oct 2015

Single drop of blood in the brain can activate autoimmune response akin to multiple sclerosis

A new study from the Gladstone Institutes shows that a single drop of blood in the brain is sufficient to activate an autoimmune response akin to multiple sclerosis (MS). This is the first demonstration that introduction of blood in the healthy brain is sufficient to cause peripheral immune cells to enter the brain, which then go on to cause brain damage.

12 Oct 2015

Research finding offers hope for more powerful aspirin-like drugs

Researchers have found that salicylic acid targets the activities of HMGB1, an inflammatory protein associated with a wide variety of diseases, offering hope that more powerful aspirin-like drugs may be developed.

11 Oct 2015

Roche to acquire biotechnology company, Adheron Therapeutics

Adheron Therapeutics, a privately held biotechnology company based in Berkeley, California, United States, announced today that it has agreed to be acquired by Roche.

9 Oct 2015

Brain & Behavior Research Foundation to honor nine scientists with Outstanding Achievement Prizes

The Brain & Behavior Research Foundation will honor nine scientists with its 2015 Outstanding Achievement Prizes for their work in schizophrenia, mood disorders, child and adolescent psychiatry, and cognitive neuroscience.

9 Oct 2015

People with restless legs syndrome at higher risk for stroke, heart and kidney disease

Imagine trying to lie down and rest but feeling an uncontrollable urge to keep moving your legs. That, in a nutshell, is the ongoing ordeal facing people with restless legs syndrome. Considered a neurological, sleep, or movement disorder, RLS affects up to 1 in 10 people in the U.S. For those coping with a more severe form of RLS, countless sleepless nights--during which they may toss and turn constantly, or get up and pace the floor--can shatter quality of life.

9 Oct 2015

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.

9 Oct 2015

High levels of satiety hormone leptin contribute to cardiovascular disease in obese individuals

While high levels of the satiety hormone leptin don't help obese individuals lose weight, they do appear to directly contribute to their cardiovascular disease, researchers report.

8 Oct 2015

Provepep synthesizes bioactive homodimer form of IL-10 using SEA peptide ligation technology

Provepep, the peptide business unit of Provence Technologies Group, a specialist fine chemistry research group, today announces that it has successfully synthesized tens of mg of bioactive homodimer form of IL-10.

7 Oct 2015

New capsule form of FMT raises hopes for treating C. difficile infection

A new capsule form of faecal microbiota transplantation (FMT) has raised hopes that this effective treatment for Clostridium difficile (C. difficile) infection and other bowel conditions might soon become mainstream. A recently-reported study confirmed that capsules containing a frozen suspension of faecal material harvested from healthy unrelated donors was well tolerated and effectively resolved diarrhoea in 90% of patients with difficult-to-treat C. difficile infection.

7 Oct 2015

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that it will provide clinical laboratory testing using the PD-L1 IHC 22C3 PharmDx immunohistochemistry companion diagnostic.

From Quest Diagnostics 7 Oct 2015

NIH researchers discover why certain immune responses can be harmful to the brain

National Institutes of Health scientists studying inflammation of the brain have discovered why certain immune responses, which typically help cells recognize and fight viral and bacterial infections, can sometimes be harmful to the brain. Many brain disorders involve the death of neurons, or nerve cells, but how these neurons die is not well understood.

7 Oct 2015

Envisia's ENV515 (travoprost XR) meets primary efficacy endpoint in phase 2a glaucoma trial

Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today reported results from its first clinical trial of the Company's lead product candidate, ENV515 (travoprost XR).

6 Oct 2015

Georgia State University researcher receives $1.35 million federal grant to study effects of emulsifiers

Andrew Gewirtz, a professor in the Institute for Biomedical Sciences at Georgia State University, has received a four-year, $1.35 million federal grant to study how emulsifiers affect bacteria in the intestinal tract and cause chronic inflammatory diseases in the gut.

6 Oct 2015

Minor infections, inadequate vaccinations increase stroke risk in children

Children who have suffered recent infections or have not received most or all of their vaccinations are at a higher risk for stroke, according to research published in the Sept. 30 issue of Neurology, the medical journal of the American Academy of Neurology.

1 Oct 2015

Presence of blood eosinophilia during NEC predicts life-threatening complications for preemies

Premature infants have heightened risks of deadly diseases because their organs and immune systems are not fully developed. Necrotizing enterocolitis (NEC), a major gastrointestinal disease that causes the intestines to die, is a leading cause of death among these infants and is the most the common disease for babies born before 32 weeks.

1 Oct 2015

Brodalumab therapy achieves 100% reduction in psoriasis symptoms

An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers and published online today in the New England Journal of Medicine.

1 Oct 2015

New study identifies inflammatory lung disease as risk factor for insulin resistance, diabetes

Numerous studies have identified obesity and poor diet as risk factors for insulin resistance and diabetes. A new study adds another risk factor to the list: inflammatory lung disease. Published in the American Journal of Physiology—Regulatory, Integrative and Comparative Physiology, the study reports that inflammation in the lungs is enough to induce the body-wide inflammation that can lead to insulin resistance.

30 Sep 2015

Inflammation News and Research

Researchers identify new therapeutic target for Duchenne muscular dystrophy

Researchers find protein that plays crucial role in development of allergic airway inflammation

Glycan binding proteins modify parasite infection in cells of the heart muscle

Single drop of blood in the brain can activate autoimmune response akin to multiple sclerosis

Research finding offers hope for more powerful aspirin-like drugs

Roche to acquire biotechnology company, Adheron Therapeutics

Brain & Behavior Research Foundation to honor nine scientists with Outstanding Achievement Prizes

People with restless legs syndrome at higher risk for stroke, heart and kidney disease

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

High levels of satiety hormone leptin contribute to cardiovascular disease in obese individuals

Provepep synthesizes bioactive homodimer form of IL-10 using SEA peptide ligation technology

New capsule form of FMT raises hopes for treating C. difficile infection

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

NIH researchers discover why certain immune responses can be harmful to the brain

Envisia's ENV515 (travoprost XR) meets primary efficacy endpoint in phase 2a glaucoma trial

Georgia State University researcher receives $1.35 million federal grant to study effects of emulsifiers

Minor infections, inadequate vaccinations increase stroke risk in children

Presence of blood eosinophilia during NEC predicts life-threatening complications for preemies

Brodalumab therapy achieves 100% reduction in psoriasis symptoms

New study identifies inflammatory lung disease as risk factor for insulin resistance, diabetes

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News